Duxton Farms and Select Harvests have been impacted by the floods
Nick Sundich, March 22, 2023
Duxton Farms (ASX:DBF) and Select Harvests (ASX:SHV) have been among the first ASX agriculture stocks to outline how recent floods have impacted them.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Duxton Farms sees a 78% reduction in total harvest
Duxton Farms told shareholders that ~70% of its portfolio in the Forbes area of NSW was subject to inundation.
The final harvest figure (of wheat, barley and canola combined) was just 8,262t , compared to the 37,241t harvested in the last season.
Investors don’t appear to have punished the stock too substantially, noting that the harvest met or exceeded internal baseline standard. And it did not downgrade its previous guidance of $8m in revenue and a $6.2m loss.
Select Harvests hit too
As for Select Harvests, Australia’s 2nd largest almond grower, told shareholders its 2023 crop volume could be lower than previous guidance issued less than a month ago.
Initial data has indicated that the volume is potentially 23-35% less than initially forecast.
Unlike Duxton Farms, Select Harvests did not blame any specific flooding events. Nevertheless, it noted that it was a poor bloom period and that there were unusually colder and wetter conditions throughout the growing season.
All this being said, almond prices have been booming in the last 12 months, so the hit to the company’s bottom line may not be as bad as it would have been otherwise.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Prescient Therapeutics (ASX:PTX): Its taken the plunge into a Phase 2 trial against T-Cell Lymphoma
There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…
Botanix Pharmaceuticals (ASX:BOT): Did it deserve to crash over 50% earlier this week?
Botanix Pharmaceuticals (ASX:BOT) crashed over 50% back on Tuesday after an update that left investors disappointed. A crash of this…
How can an investor beat the market? Here’s how to go about it
You may’ve heard the expression to ‘beat the market’. What does this mean? Well, it depends on the context in…